Antimetabolites: all 7,305 studies that test it

Page 36 of 74. Open to participants first (1,098), then studies with results posted, then the rest; newest registration first within each.

• Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor BurdenStatus unknownNCT04553393Phase 1/2
• Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)Status unknownNCT04552093Phase 2/3
• Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaTerminatedNCT04550442Phase 1/2
• A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological MalignanciesActive, not recruitingNCT04547049Phase 3
• Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic AdenocarcinomaActive, not recruitingNCT04543071Phase 2
• Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST TrialSuspendedNCT04539366Phase 1
• Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal CancerCompletedNCT04534218Phase 2
• Comparison of Methylprednisolone or Methotrexate in the Maintenance Treatment of Nasal PolyposisCompletedNCT04532736Phase 2
• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsActive, not recruitingNCT04530565Phase 3
• Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
• Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural MesotheliomaCompletedNCT04525859Phase 1
• Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric AdenocarcinomaActive, not recruitingNCT04523818Phase 1
• PRECISE CURATE.AI Pilot Clinical TrialStatus unknownNCT04522284Phase 1/2
• Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain CancerWithdrawnNCT04521946Phase 1
• Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal JunctionCompletedNCT04517747Not applicable
• Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)Active, not recruitingNCT04515615Phase 2
• A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCCStatus unknownNCT04514835Phase 2
• Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS LymphomaStatus unknownNCT04514393Phase 2
• Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)Status unknownNCT04510818Phase 1
• Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin LymphomaStatus unknownNCT04510610Phase 2/3
• A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)CompletedNCT04509622Phase 3
• Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)Status unknownNCT04508686Phase 1
• Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLCCompletedNCT04507217Phase 2
• Azacitidine and Homoharringtonine in JMMLStatus unknownNCT04505995Not applicable
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene MutationStatus unknownNCT04500717Phase 3
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Phase 3
• Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic CancerStatus unknownNCT04498689Phase 2
• Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsActive, not recruitingNCT04493138Phase 1/2
• Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnNCT04493099Phase 1/2
• Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AMLStatus unknownNCT04490707Phase 3
• TAS102 in Patients With ER-positive, HER2-negative Advanced Breast CancerCompletedNCT04489173Phase 2
• Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDSSuspendedNCT04485065Phase 1
• Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)Active, not recruitingNCT04483466Phase 3
• Repeated Methotrexate for Proliferative Vitreoretinopathy Grade CStatus unknownNCT04482543Phase 2/3
• SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IICompletedNCT04480372Phase 2
• Neoadjuvant Therapy in Biliary AdenocarcinomaWithdrawnNCT04480190Phase 1
• Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional ChemotherapyStatus unknownNCT04480125Phase 2
• Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCTActive, not recruitingNCT04476199Phase 2
• Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid ArthritisStatus unknownNCT04464642Phase 4
• Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.Status unknownNCT04453423Phase 2
• Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal CancerTerminatedNCT04450836Phase 2
• Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.TerminatedNCT04425655Phase 2
• Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer PatientsCompletedNCT04425564Phase 2
• Neoadjuvant Therapy for Localized Rectal AdenocarcinomaWithdrawnNCT04418895Phase 2
• The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal CancerStatus unknownNCT04411537Phase 2
• The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal CancerStatus unknownNCT04411524Phase 2
• Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.Status unknownNCT04405622Phase 2
• Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and NeckCompletedNCT04397341Phase 2
• Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901Status unknownNCT04396457Phase 2
• Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04390958Phase 2
• Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT04390399Phase 2
• Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)Active, not recruitingNCT04383275Phase 2
• Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingNCT04379596Phase 2
• Surgery Alone Versus Methotrexate Before Surgery in Cesarean Scar PregnancyStatus unknownNCT04379219Phase 4
• Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerStatus unknownNCT04377048Phase 2
• IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMMLCompletedNCT04372433Phase 1
• Leflunomide for the Treatment of High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT04370483Early Phase 1
• Neo-adjuvant Short Course Chemo-radiation Therapy in Locally Advanced Rectal Cancer PatientsStatus unknownNCT04370418Phase 2/3
• Allopurinol in Patients With Refractory Angina to Improve Ischemic SymptomsStatus unknownNCT04368819Phase 2/3
• Reduced Intensity Transplantation for Severe Sickle Cell DiseaseActive, not recruitingNCT04362293Phase 2
• Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT04361409Phase 1
• Leflunomide in Mild COVID-19 PatientsTerminatedNCT04361214Phase 1
• Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in SpondyloarthritisCompletedNCT04360785Not applicable
• Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric CancerStatus unknownNCT04358341Phase 2
• D-cycloserine Augmented Treatment for Youth With Tic DisordersWithdrawnNCT04357951Early Phase 1
• Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal CancerCompletedNCT04357587Phase 1
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric CancerCompletedNCT04354662Phase 2
• Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid LeukemiaStatus unknownNCT04353479Phase 2
• Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 PatientsStatus unknownNCT04352465Phase 1/2
• A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric CancerStatus unknownNCT04351867Phase 3
• Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic CancerActive, not recruitingNCT04340141Phase 3
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBCActive, not recruitingNCT04335669Phase 3
• Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLCStatus unknownNCT04331626Phase 4
• A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511TerminatedNCT04327011Phase 1
• Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal CarcinomaStatus unknownNCT04319471Phase 2
• Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib ResistanceStatus unknownNCT04316351Phase 2
• Effectiveness of Methotrexate Versus Prednisone as First-line Therapy for Pulmonary SarcoidosisActive, not recruitingNCT04314193Phase 4
• A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGCCompletedNCT04309578Phase 2
• The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic PregnancyStatus unknownNCT04308343Not applicable
• NX in Luminal B Breast Cancer Patients After Neoadjuvant ChemotherapyStatus unknownNCT04307147Phase 3
• Adjuvant Chemotherapy in High Risk Stage II Colon CancerStatus unknownNCT04303429Phase 3
• A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant ChemotherapyStatus unknownNCT04302441Phase 2
• A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant ChemotherapyStatus unknownNCT04297267Phase 2
• Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal CancerStatus unknownNCT04296240Phase 2
• Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)CompletedNCT04296162Phase 2
• PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After SurgeryActive, not recruitingNCT04295317Phase 2
• TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon CancerActive, not recruitingNCT04294264Phase 2
• Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major ThalassemiaCompletedNCT04292314Phase 2/3
• CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic MalignanciesWithdrawnNCT04282174Phase 2
• Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaCompletedNCT04281576Not applicable
• Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)Active, not recruitingNCT04280536Phase 1/2
• Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell LymphomaStatus unknownNCT04279379Phase 2
• A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor TherapyTerminatedNCT04274933Phase 1
• CPX-351 in Higher Risk Myelodysplastic SyndromesCompletedNCT04273802Phase 1/2
• Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated PatientsStatus unknownNCT04269369Phase 4
• A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677CompletedNCT04268394Phase 1
• A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)WithdrawnNCT04264806Phase 2
• Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic MalignanciesStatus unknownNCT04264078Early Phase 1
• Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute LeukemiaActive, not recruitingNCT04262843Phase 2

← Antimetabolites overview